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This study examined the hypothesis that developmental expression of psychometric risk in the 
form of subclinical psychotic experiences in the general population is usually transitory but in 
some instances may become abnormally persistent and progress to a clinical psychotic state. 
A prospective cohort study was conducted in a general population sample of 845 adolescents, 
aged 14–17 years, in Munich, Germany (Early Developmental Stages of Psychopathology 
Study). Expression of psychosis was assessed 4 times (T0–T3) over a period of 8.4 years. 
Transition from subclinical psychosis at T0–T2 to clinical psychosis in terms of impairment at 
T3 was examined as a function of the level of prior persistence of subclinical psychosis 
(present never, once, twice, or thrice). The more the subclinical psychosis persisted over the 
period T0–T2, the greater the risk of transition to clinical psychosis at T3 in a dose-response 
fashion (subclinical psychosis expression once over T0–T2: odds ratio [OR] 5 1.5 [95% 
confidence interval {CI} 5 0.6–3.7], posttest probability [PP] 5 5%; twice: OR 5 5.0 [95% 
CI51.6–15.9], PP 5 16%; at all 3 measurements: OR 5 9.9 [95% CI 5 2.5–39.8], PP 5 27%). 
Of all clinical psychosis at T3, more than a third (38.3%) was preceded by subclinical 
psychotic experiences at least once and a fifth (19.6%) at least twice. Consequently, a 
significant proportion of psychotic disorder may be conceptualized as the rare poor outcome 
of a common developmental phenotype characterized by persistence of psychometrically 
detectable subclinical psychotic experiences. This may be summarized descriptively as a 
psychosis proneness-persistence-impairment model of psychotic disorder.  
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Introduction  
 
Psychosis is commonly considered a rare phenomenon outside the range of normal human 
experience, giving rise to significant disability. However, the type of distribution expected for 
disorders of multifactorial interactive etiologies is continuous,1,2 and many mental disorders 
have accordingly been shown to exist along a spectrum including subclinical expressions, 
evidenced by, eg, relatively high rates of expression of bipolar spectrum symptoms, 
subthreshold depressive states, and social restriction associated with autism.3–6  
 
Similar findings have been reported for psychosis.1 The clinical psychosis phenotype has not 
only been shown to be much less rare than previously thought7 but is also thought to be 
expressed at levels well below its clinical manifestation.8–11 Apart from strong evidence of 
phenomenological continuity in form and structure,1 continuity between clinical and 
subclinical phenotypes is further suggested by (1) similar associations with demographic 
factors, in particular the negative association with age and the positive association with single 
marital status and social disadvantage,1,10,12,13 (2) transitions over time from the subclinical to 
the clinical,8,14,15 (3) familial co-clustering of the clinical and the subclinical,16 (4) strong 
dose-response effects of the urban environment on both phenotypes,17 (5) sharing of cognitive 
and motor deficits,18,19 and (6) sharing of risk genes20 and of environmental risk factors such 
as cannabis.21  
 
Many questions remain, however, with regard to the hypothesized continuity over time from 
subclinical to clinical psychotic states. The seminal study by Poulton et al14 demonstrated that 
more than 25% of participants with low-grade psychotic experiences at age 11 years 
developed a clinical psychotic disorder by age 26 years. However, an equally important 
conclusion of the study was that the great majority of children with expression of psychotic 
experiences would never develop a psychotic disorder – psychosis was only a transitory 
developmental state for most. Similar conclusions were reached by other, less lengthy follow-
up studies in adult population cohorts, with transition rates of around 10%.8,15 Cougnard et 
al22 recently suggested that one of the reasons why most developmental expression of 
psychosis remains transitory is that exposure to additional environmental risks over 
development, such as cannabis use, childhood trauma, and urban environment, is necessary in 
order for subclinical psychosis to first become persistent and, second, to deteriorate into a 
clinical psychotic state (figure 1). However, to date, no evidence has been presented 
suggesting that abnormal persistence of a common and normally transitory developmental 
subclinical psychosis phenotype is the precursor state of clinical deterioration.  
 
In the current article, it was examined whether subclinical psychotic experiences with a 
greater tendency to persist over time would have a greater probability to become clinically 
relevant in terms of dysfunction and need for care (impairment). The hypothesis of greater 
persistence resulting in greater probability of transition from subclinical to clinical psychosis 
characterized by impairment was tested using a prospective, observational study in a large, 
general population sample of adolescents followed over a period of more than 8 years.  
 
Method  
 
Sample  
 
Data came from the Early Developmental Stages of Psychopathology (EDSP) Study, which 
collected data on the prevalence, incidence, risk factors, comorbidity, and course of mental 
disorders in a random, representative population sample of adolescents and young adults in 
the general population. The baseline sample, following ethics committee approval, was 
randomly drawn, in 1994, from the respective population registry offices of Munich and its 29 
counties, to mirror the distribution of individuals expected to be 14–24 years of age at the 
time of the baseline (T0) interview in 1995. The base population were all those born between 
June 1, 1970, and May 31, 1981, registered as residents in these localities and having German 
citizenship. These registers can be regarded as highly accurate because (1) each German is 
registered by his town, (2) they are regularly updated, (3) in the interest of scientific studies, 
any number of randomly drawn addresses with a given sex and age-group can be obtained, 
and (4) strict enforcement of registration by law and the police applies. More details on the 
sampling, representativeness, instruments, procedures, and statistical methods of the EDSP 
Study sample have previously been presented.23,24  
 
Study Design  
 
The overall design of this cohort study is longitudinal and prospective, consisting of a 
baseline (T0) and 3 follow-up surveys, covering a time period of on average 1.6 years (T0–
T1, SD = 0.2), 3.5 years (T0–T2, SD = 0.3), and 8.4 years (T0–T3, range = 7.3–10.5 y, SD = 
0.7). Because the primary goal of the study was to examine the incidence and developmental 
risk factors for psychopathology, the younger group (14–15 y), presumed to have the highest 
incidence density, was sampled at twice the rate of persons aged 16–21 years, and the oldest 
group (22–24 y) was sampled at half this rate. For the same reason, subjects aged 14–17 years 
at baseline were examined at the 4 time points, and subjects aged 18–24 years were assessed 
only 3 times.  
 
The present study is based on a subset of EDSP Study respondents, namely, the younger 
cohort (aged 14–17 y at baseline) only (T0, n = 1395, response rate = 75%), thus ensuring an 
adolescent population at risk of developing psychotic experiences and subsequent transition to 
clinically relevant psychotic states over 4 assessment periods. Response rates for the younger 
cohort were respectively 88% at T1 (n = 1228), 83% at T2 (n = 1169), and 73% at T3 (n = 
1022). After description of the study to the subjects, written informed consent was obtained.  
 
Instruments  
 
The Self-report Symptom Checklist-90-R. At all time points, participants completed the self-
report symptom checklist-90-R (SCL-90-R), a comprehensive self-report symptom inventory, 
multidimensional in nature, and oriented to screen for a broad range of psychological 
problems and psychopathology in community respondents and respondents with somatic and 
psychiatric disorders. It contains 90 items, scored on a 5-point severity scale, measuring 9 
primary symptom dimensions named „somatization,“ „obsessive-compulsive,“ „interpersonal 
sensitivity,“ „depression,“ „anxiety,“ „hostility,“ „phobic anxiety,“ „paranoid ideation,“ and 
„psychoticism.“  
 
Reliability and validity of the SCL-90-R were established previously.25 The time frame is the 
past 2 weeks.  
 
The Munich-Composite International Diagnostic Interview. Participants were also assessed 
using the computerized version of the Munich-Composite International Diagnostic Interview 
(DIA-X/M-CIDI),26 an updated version of the World Health Organization’s CIDI version 
1.2.27 The DIA-X/M-CIDI is a comprehensive, fully standardized diagnostic interview and 
assesses symptoms, syndromes, and diagnoses of various mental disorders in accordance with 
the definitions and criteria of the International Classification of Diseases, Tenth Revision, and 
Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), along with 
information about onset, duration, severity of symptoms, and psychosocial impairment. The 
CIDI has been primarily designed for use in epidemiological studies of mental disorders and 
can also be used for clinical purposes. It is divided into 16 sections: 1 sociodemographic 
section, 12 sections assessing 288 symptoms of groups of mental disorders (including 
„somatoform and dissociative,“ „phobic and other anxiety,“ „depressive and dysthymic,“ 
„manic and bipolar affective,“ „schizophrenia and other psychotic,“ „eating,“ „dementia and 
other cognitive,“ „posttraumatic stress,“ as well as „tobacco,“ „alcohol,“ and „substance-
related“ disorders), and 3 final sections containing concluding questions, interviewer 
observations, and interviewer ratings.  
 
The instrument, designed for use by trained interviewers who are not clinicians, has shown 
high interrater (j>0.70)28,29 and test-retest reliability.30,31 However, the assessment of 
psychosis with CIDI by lay interviewers is not considered reliable.30,32 Therefore, in the EDSP 
Study, trained and experienced clinical interviewers at the level of psychologist, who were 
allowed to probe with follow-up clinical questions, conducted the interviews in the 
respondents’ homes.  
 
At baseline, the DIA-X/M-CIDI lifetime version was used. At each of the follow-up 
assessments, participants applied the interval version, which covers the period of assessment 
from the last interview until the next. However, data on the G section concerning psychosis 
and its clinical relevance were only collected at time point 2 (lifetime version) and time point 
3 (interval version).  
 
Construction of SCL-Psychosis Subscale  
 
The 2 symptoms dimensions relevant for psychosis of the SCL-90-R, the so-called paranoid 
ideation and psychoticism subscales, were used to assess persistence of psychotic experiences 
over the period T0–T3. The 2 subscales include self-reports on psychotic experiences that can 
be regarded, if not as clear-cut psychotic symptoms, as a subclinical expression of psychotic 
experiences. The 6-item paranoid ideation subscale represents paranoid behavior 
fundamentally as a disordered mode of thinking, including the cardinal characteristics of 
projective thought, hostility, suspiciousness, grandiosity, centrality, and fear of loss of 
autonomy (items 8, 18, 43, 68, 76, and 83). The 10-item psychoticism subscale was developed 
in a fashion to represent the construct as a continuous dimension of human experience, 
including items indicative of a withdrawn, isolated, schizoid lifestyle, and first-rank 
symptoms of schizophrenia, such as hallucinations and thought broadcasting (items 7, 16, 35, 
68, 77, 84, 85, 87, 88, and 90). The severity scale of each symptom was scored from „not at 
all“ (0) to „extremely“ (4). The psychoticism and paranoia scales are strongly correlated (in 
the current sample, mean correlation over T0–T3 was .7), and the items in the scales have 
high predictive validity for future deficiency in social achievement and functioning.33 
Therefore, conform previous research in this sample,17,34 the psychoticism and paranoid 
ideation subscales were combined into one Psychosis scale (hereafter „SCL-psychosis 
subscale“) by summing their scores. The resulting SCL-psychosis subscale thus was a 
continuous score displaying a half-normal distribution at all time points (T0–T3). Previous 
research has shown that instruments assessing psychotic experiences dimensionally typically 
display a half-normal distribution.2  
 
Assessment of Persistence of Psychotic Experiences Over the Period T0–T2  
 
In order to examine the hypothesis relating to persistence over time, a discrete variable 
indicating presence or absence of psychosis across interview waves was, per definition, 
necessary. For the purpose of the analyses, a dichotomous psychosis variable was created 
using a cutoff point to define the group of individuals with the highest 10% of scores of the 
SCL-psychosis subscale (hereafter „psychosis expression“), consistent with previous analyses 
in this sample22,34 and congruent with the meta-analytic rate for the prevalence of psychotic 
symptoms in the general population.2 Nevertheless, as a 10% cutoff remains arbitrary, 
sensitivity analyses were conducted using more and less conservative cutoff point values of 
the highest 5% and the highest 15% of the SCL-psychosis subscale.  
 
A variable was defined indicating the degree of persistence of psychotic experiences over the 
period T0–T2. This resulted in a summary score variable consisting of 4 levels of psychosis 
expression: never (0), once (sporadic) (1), twice (recurrent) (2), and thrice (persistent) (3). 
This variable will hereafter be referred to as „psychosis persistence.“  
 
Assessment of Clinical Relevance of Psychotic Experiences at T2 and T3  
 
Clinical relevance related to psychotic experiences was assessed by interview ratings from the 
DIA-X/M-CIDI in terms of psychotic impairment, representing the first step that needs 
explaining and predicting in tracking the ontogenesis of psychotic disorder in the general 
population. In order to define psychotic impairment, secondary dysfunction and help-seeking 
behavior were only examined in individuals with evidence of DIA-X/MCIDI–positive 
psychotic symptoms at T2 (lifetime) and T3 (interval version).  
 
Presence of positive psychotic experiences was broadly defined as any rating of „present“ on 
any of the 20 DIAX/ M-CIDI core psychosis items (G1, G2a, G3–G5, G7–G13, G13b, G14, 
G17, G18, G20, G20C, G21, and G22a), including 14 delusion items, 5 hallucination items, 
and 1 item on passivity phenomena. Items relate to classic psychotic symptoms involving, eg, 
persecution, thought interference, auditory hallucinations, and passivity phenomena. 
Participants were first invited by the psychologist to read a list of all the psychotic 
experiences and then asked whether they ever experienced such symptoms (list and phrasing 
available upon request). All these psychosis items were rated in 2 ways: absent (1) and 
present (5); all the psychosis DIA-X/M-CIDI items used in the present study were coded in a 
dichotomous manner without intermediate levels.  
 
Help Seeking. Help-seeking behavior secondary to psychotic experiences was assessed using 
3 DIA-X/M-CIDI items. Two psychosis section items were used: G16 (delusions) and G23 
(hallucinations), which were phrased as follows: „Did you tell a doctor about … (the 
psychosis section beliefs/experiences previously acknowledged by the participant along with 
a visual representation from the response booklet) you have had?“ A third item from the 
concluding section was added (Q1DG); participants were shown a list on which several types 
of outpatient or inpatient institutions for mental health problems were mentioned, ranging 
from general practitioner or school psychologist to psychiatric sheltered housing, and asked 
whether they had ever sought help at any of these institutions because of psychotic symptoms 
as elicited in the DIA-X/M-CIDI G section. The 3 items were rated in a dichotomous manner: 
no (1) and yes (5). Using these 3 help-seeking behavior items, a dichotomous variable „help 
seeking“ was constructed, indicating a positive answer on any of the 3 questions (value label: 
1) vs negative answers on all 3 questions (value label: 0).  
 
Dysfunction. The dysfunction score of the psychosis DIA-X/M-CIDI section assessed the 
effect of the psychotic experiences on (1) feeling upset, unable to work, go to places, or enjoy 
oneself, at the time of having these experiences (item G28), (2) being less able to work since 
these experiences began (item G29), (3) being less able to make friends or enjoy social 
relationships since these experiences began (item G29a), and (4) how much their life and 
everyday activities were impaired when these experiences were at their worst (item G36). 
These 4 items were rated in a dichotomous manner: no (1) and yes (5).A dichotomous 
variable „dysfunction“ was dichotomously constructed, representing a positive answer on any 
of the 4 questions (value label: 1) vs negative answers on all 4 questions (value label: 0).  
 
The Outcome Measure: Psychotic Impairment. Clinically relevant psychosis was finally 
defined in terms of „psychotic impairment,“ a variable created as a combined outcome of help 
seeking and dysfunction. This was rated as „0“ in subjects with psychotic experiences who 
scored „0“ on both help seeking and dysfunction and „1“ in subjects scoring „1“ on either or 
both help seeking and dysfunction.   
 
Caseness. In order to validate the outcome measure psychotic impairment in terms of clinical 
relevance, the X16 DIA-X/M-CIDI item was used. This item, rating the interviewer’s opinion 
regarding clinical evidence of psychological ill health, consists of 4 levels: essentially not 
noticeable (0), not very noticeable (1), clearly ill (2), and very ill (3). The dichotomous 
variable „caseness“ was defined as any score above 1, thus indicating individuals with a 
noticeable level of psychiatric caseness.  
 
Risk Set  
 
All the analyses were conducted in the younger cohort who (1) had been examined in the 4 
waves of the study, (2) had completed the psychoticism and paranoia SCL-90-R subscales at 
T0–T3, and (3) had completed the DIA-X/M-CIDI psychosis G section at T2 and T3 (n = 
845). Of the 1395 individuals in the younger cohort at baseline, 845 fulfilled the risk set 
criteria.  
 
Of the 1022 participants belonging to the younger cohort that completed the 4 waves, 94 
individuals did not complete the self-report SCL-90-R at T1, 65 at T2, and 13 at T3. In 
addition, the G section of the DIA-X/M-CIDI was not available for 5 participants at T2. This 
resulted in a risk set of 845 participants who were included in the analysis.  
 
Thus, a risk set of 845 participants remained from the total number of 1395 participants that 
composed the younger cohort at baseline. Of the 550 individuals not included in the risk set 
(hereafter: „nonincluded group“), the reason was loss to follow-up over the 8-year period in 
373 and partial nonresponse in 177.  
 
Statistical Analyses  
 
All analyses were conducted using the software package STATA, version 9.2 (Stata 
Corporation, College Station: TX; 2006).  
 
In order to examine representativeness, the risk set (n = 845) was compared with the 
nonincluded group (n = 550) in terms of sociodemographic characteristics such as age, 
gender, level of education, social status, and urban residence.  
 
The focus of the study was on psychosis persistence in adolescents over a period of 
approximately 3.5 years (T0–T2), integrating the scores of 3 waves (T0, T1, and T2) and 
analyzing the influence of the degree of persistence on the onset of psychotic impairment at 
T3 (figure 1). To this end, logistic regression analyses were performed to examine the 
associations between T0–T2 psychosis persistence on the one hand and T3 psychotic 
impairment on the other. Associations were expressed as odds ratios (ORs) and their 95% 
confidence intervals (CIs). In order to ensure that the analyses focused on true new onsets of 
psychotic impairment at T3, any individual with psychotic impairment assessed lifetime at T2 
was excluded.  
 
In order to calculate posttest probabilities (PPs) for T0–T2 psychosis persistence in relation to 
the T3 outcome of psychotic impairment, excluding any individual with lifetime T2 psychotic 
impairment, the STATA DIAGTEST procedure was used.  
 
For both the logistic regression analyses and the calculation of PPs, a further check was 
introduced by additionally excluding individuals reporting at T2 that they had received any 
professional help for any psychological problem (DIA-X/M-CIDI Q1 item).  
 
In addition, sensitivity analyses were conducted using more and less conservative cutoff point 
values of the highest 5% and the highest 15% of the SCL-psychosis subscale. Logistic 
regression was used to validate the T3 outcome measure psychosis impairment against the T3 
caseness variable.  
 
Results  
 
Subject Characteristics  
 
The average age of the risk set at T0 was 15.08 years (range = 14–17; SD = 1.1). Of all 
participants, 444 were boys (52.5%) and 401 girls (47.5%). Other demographic characteristics 
are depicted in table 1.  
 
In comparison with the risk set (n = 845), individuals from the nonincluded group (n = 550) 
were of similar age (mean age = 15.18 y), gender distribution (boys: 49.1%), or urban 
residence (69.1% vs 72% for included vs nonincluded, respectively). The nonincluded group 
had a lower level of education (included lower level: 9.7% vs nonincluded lower level: 
28.6%; v2 = 100.41, P = .000) and lower social status (included lower status: 3.4% vs 
nonincluded lower status: 6.6%; v2 = 12.36, P = .006).  
 
Occurrence of Psychotic Experiences  
 
The mean score of the continuous SCL-psychosis subscale was 21.5 (SD = 5.6) at T0, 19.5 
(SD = 4.9) at T1, 19.5 (SD = 4.7) at T2, and 18.7 (SD = 4.7) at T3. With the interview ratings 
of the DIA-X/M-CIDI, the lifetime prevalence of psychotic symptoms at T2 was 21.8% (n = 
184), and the interval cumulative incidence of psychotic symptoms at T3 was 12.7% (n = 
107).  
 
The distribution of the SCL-90-R psychosis persistence variable over T0–T2 was never: 
78.9% (n = 666), once (sporadic): 15.6% (n = 132), twice (recurrent): 3.9% (n = 33), and 
thrice (persistent): 1.7% (n = 14). Of the 83 individuals with psychosis expression at T0, 32 
(38.6%) again had psychosis expression at either T1 or T2. Of the 72 individuals with 
psychosis expression at T1, 29 (40.3%) had psychosis expression at T2. Based on the DIA-
X/M-CIDI interview ratings, of the 184 (21.8%) individuals with any DIA-X/M-CIDI 
psychotic symptom at T2, 51 (27.7%) again had evidence of psychotic symptoms at DIA-
X/M-CIDI interview at T3.  
 
Occurrence of Psychotic Impairment  
 
Of the 184 individuals with lifetime presence of DIA-X/ M-CIDI psychotic symptoms at T2, 
64 (34.8%) had evidence of psychotic impairment. Of the 107 individuals with interval 
presence of DIA-X/M-CIDI psychotic symptoms at T3, 45 (42.1%) had evidence of psychotic 
impairment.  
 
Of the 64 individuals with psychotic impairment at T2, 11 (17.2%) had again evidence of 
psychotic impairment at T3.  
 
Proportion of T3 Psychotic Impairment With Prior T0–T2 Psychosis Expression  
 
In terms of attributable risk, of the 47 individuals who displayed T3 psychotic impairment, 18 
(38.3%) had evidence of psychosis expression at any time point between T0 and T2, of which 
9 (19.6%) more than once.  
 
Transition to T3 Psychotic Impairment  
 
There was a strong association between T3 psychotic impairment and the T3 clinical caseness 
variable (OR = 9.4, 95% CI = 3.1–28.6).  
 
The absolute rate and relative risk of onset of T3 psychotic impairment as a function of the 
degree of T0–T2 psychosis persistence are depicted in table 2. Excluding those with lifetime 
evidence of psychotic impairment at T2, the rates of T3 transition to psychotic impairment at 
the 4 levels of psychosis persistence (from 0 to 3) were 3.7% (n = 23), 5.3% (n = 6), 16.0% (n 
= 4), and 27.3% (n = 3), yielding ORs (levels 1–3 relative to 0) of 1.5 (95% CI = 0.6–3.7; p = 
.414), 5.0 (95% CI = 1.6–15.9; p = .006), and 9.9 (95% CI = 2.5–39.8; p = .001), respectively. 
Additional exclusion of those with T2 receipt of professional help for mental ill health 
similarly did not change these results (ORs of 1.1 [95% CI = 0.4–3.2; p = .893], 3.1 [95% CI 
= 0.7–14.0; p = .151], and 16.5 [95% CI = 3.7–73.6; p = .000], respectively).  
 
Sensitivity analyses, using more and less conservative cutoff values for the SCL-psychosis 
subscale, showed the same pattern of increase in the rates of T3 transition to psychotic 
impairment. Thus, for the more conservative 5% cutoff, risk of transition increased from the 
sporadic (OR = 2.8, 95% CI = 1.1–7.1) to the persistence level (OR = 12.6, 95% CI = 1.1–
143.2). For the less conservative 15% cutoff, risk for transition increased similarly from the 
sporadic (OR = 1.6, 95% CI = 0.7–3.7) to the persistence level (OR = 7.5, 95% CI = 2.3–
24.8).  
 
The PPs for T0–T2 psychosis persistence in relation to T3 psychotic impairment, excluding 
individuals with lifetime evidence of T2 psychotic impairment, increased progressively from 
the sporadic (PP = 5.3%; 95% CI = 3.7%– 6.9%) to the persistence level (PP = 27.3%; 95% 
CI = 23.8%–30.7%) (table 2). Predictive values were even higher when the risk set was 
additionally restricted to individuals with no T2 receipt of professional help for mental health 
problems (table 2).  
 
 
 
 
 
Discussion  
 
Findings  
 
This is the first study examining the influence of persistence of subclinical psychotic 
experiences in a sample of adolescents and young adults in the general population in relation 
to the transition to clinically relevant psychosis. The results showed, first, that subclinical 
psychosis was confirmed to be common (psychosis expression rates of 22%) and mostly 
transitory, recurrence or persistence occurring in 30%–40% of cases. Second, the findings 
demonstrated that persistent positive symptoms at a subclinical level pose a significant risk 
and can be considered a marker of emerging clinical states. A dose-response relationship was 
found: the longer the period over which subclinical psychosis remained abnormally 
nontransitory, the greater the risk of developing associated impairment. Third, although most 
subclinical psychosis was transitory, these results showed that the impact of the relationship 
between the clinical and the subclinical was not negligible: Around two-fifths of new onset, 
clinically relevant psychosis in young adults could be traced to the subclinical psychosis 
phenotype expressed up to 8 years earlier, and one-fifth had displayed evidence of a recurrent 
or persistent subclinical phenotype. For some individuals, psychosis is thus the denouement of 
a long process of subclinical experiences and functional deficits. Consequently, these findings 
provide evidence for the continuity over time from subclinical persistent psychotic 
experiences to clinical psychotic states, yielding insight into the dynamics preceding the 
clinical onset of psychotic disorder from a population perspective.  
 
Persistence of Subclinical Psychosis Expression  
 
The recurrence-persistence rate of subclinical psychosis in this study was higher than reported 
in previous population- based studies. In a 2-year follow-up of a general population sample 
aged 18–64 years, Hanssen et al15 found a 2-year 8% persistence rate of baseline subclinical 
psychosis and an 8% transition rate from subclinical to clinical psychosis. In the present 
study, the recurrence-persistence rate was 30%–40% over time, considerably higher. The 
most likely factor to explain this difference is the much younger age of the current sample. 
Given the rapid decline of psychosis expression with age,10,12,13 continuity over time will 
become less likely with advancing age. Thus, in a previous follow-up study of adolescents, a 
3-year persistence rate was found to be 40%, similar to that of the current study.35  
 
The Persistent Subclinical Psychosis Pathway Into Clinical Psychosis  
 
Although the development of subclinical psychotic symptoms is an initial step to the 
emergence of psychotic disorder in a significant proportion of cases, not more than two-fifths 
of all psychotic impairment could be attributed to this pathway. This likely represents an 
underestimate, however, caused in part by the uneven sampling intervals from T0 to T3. Thus, 
the relatively wide sampling interval between T2 and T3 (4.9 y on average) may have resulted 
in participants underreporting experiences and instances of help seeking. Similarly, the SCL-
90-R assesses symptoms over the last 2 weeks, thus creating the possibility of underreporting 
psychotic experiences over the period T0–T2. In addition, other domains of psychopathology, 
such as depression and anxiety, may also contribute to prediction and attributable risk and 
need to be investigated further.36 Furthermore, more work is needed on the role of cognitive 
alterations in the ontogenesis of psychotic states, given the fact that meta-analytic work 
indicates that this domain is orthogonal to the positive and affective symptoms of psychosis,37 
yet is likely to impact on the domain of functional impairment in the onset of clinical 
psychotic states.  
 
Even if it represents a likely underestimation, the fact that 40% of new onset, clinically 
relevant psychosis can be traced to the early subclinical psychosis phenotype in the general 
population sheds light on the ontogenesis of psychotic states in the general population. 
However, much more work is needed in order to understand the process resulting in clinical 
need in individuals at risk, and the current findings need to be replicated before firm 
conclusions can be drawn.  
 
From Persistent Subclinical Psychosis to Impairment: Possible Mechanisms  
 
The positive psychosis pathway may be understood as the phenomenological correlate of the 
classical dopamine (DA) hypothesis that proposes that hyperactivity of DA transmission from 
DA cell bodies located in the ventral tegmental area of the midbrain to their terminal fields in 
the nucleus accumbens and limbic cortex results in the development of positive psychotic 
symptoms.38,39 DAergic hyperactivity may be associated with what has been called a state of 
endogenous sensitization.38 The liability for psychosis may involve deficits in neural 
regulation resulting in a pathological condition of neurochemical sensitization of the 
mesolimbic DAergic system analogous to the preclinical model of behavioral sensitization 
induced by administration of DA-releasing drugs.39 Behavioral sensitization is a progressive, 
enduring enhancement of behaviors that develops following repeated stimulant 
administration. It is mediated in part by DAergic pathways that are also thought to modulate 
the development of psychosis.40  
 
Endogenous neurochemical sensitization may arise in part as a result of exposure to 
environmental conditions.41 For example, environmental stress can induce sensitization and 
has been demonstrated to be cross-reactive with many types of pharmacologically induced 
sensitization, including DA and opiate agonists.39 It has been suggested that several 
environmental risk factors, eg, perinatal injury, childhood trauma, repeated life events, and 
drug abuse, may contribute to DA sensitization during development.42 It is attractive to 
speculate that a genetictendency to abnormal DA sensitization is associated with the tendency 
to express low-grade psychotic experiences that in most individuals will only be expressed 
transitorily over development. However, in the case of developmental exposure to 
environmental risk factors, individuals may develop a sensitized DA system resulting in 
abnormally persistent and, eventually, clinically relevant psychotic states.22  
 
Methodological Issues  
 
First, the dynamic hypothesis of psychosis onset was examined in the context of a large-scale 
epidemiological study not specifically designed for this purpose. It was thus constrained by 
the specific psychometric tools and sampling frame.  
 
Second, the group comparison between the risk set (n = 845) and the nonincluded group (n = 
550) showed that the latter had a lower level of education and social status. Because these are 
risk factors for psychotic experiences,1,10 attrition of these individuals may have led to an 
underestimation of psychosis outcomes in our sample. Bias of reported associations, however, 
would have occurred only in the unlikely event that high levels of psychosis persistence 
would be associated with lower rates of transition to clinical psychosis in this group.  
 
Third, in order to measure persistence of psychotic experiences, the SCL-90-R was used. The 
fact that this instrument only covers the past 2 weeks may have led to an underestimation of 
the T0–T2 psychosis persistence measure. As it is difficult to see how this would result in a 
spurious association with interviewer-assessed psychotic symptoms and impairment 5 years 
later, any error resulting from underestimation would have likely been random. Similarly, to 
the degree that the SCL-90-R overestimates the rate of psychotic symptoms (because of the 
misunderstandings arising from self-report), any resulting error would likely also be random. 
Furthermore, the way the measure of psychosis persistence in the present study was 
constructed, only considering those individuals with the highest 10% of scores of the 
continuous SCL-psychosis subscale, prevented misclassification due to overestimation of 
such experiences on the basis of incidental misunderstanding of items.  
 
Four, the DIA-X/M-CIDI was used to measure clinical relevance of psychotic experiences in 
terms of psychotic impairment, evaluating secondary dysfunction and help-seeking behavior. 
On the one hand, help seeking may have led to an underestimation of true positives in the case 
of individuals who did not seek for help in spite of suffering from true clinical psychotic 
symptoms. On the other hand, dysfunction may have led to an overestimation of true positives 
in the case that individuals reported secondary dysfunction only based on subjective level of 
distress. Nonetheless, the validation of the outcome variable against the clinical judgment of 
illness strongly supports the validity of psychotic impairment as a proxy measure of clinical 
relevance.  
 
Five, the number of cases with recurrence-persistence of psychosis expression that developed 
psychotic impairment was relatively small conform the expected low rate in the general 
population, resulting in wide CIs.  
 
Six, the main instruments to assess psychotic experiences and symptoms in the current study 
(SCL-90-R and DIA-X/M-CIDI) are essentially self-report. Although this is likely to have 
generated false-positive psychotic experiences, likely increasing random error as discussed 
earlier, there is nevertheless a substantial literature on the (predictive or other forms of) 
validity of self-reported psychotic symptoms, assessed with DIA-X/M-CIDI, SCL-90-R, and 
other instruments.2 For example, one study validated self-reported psychotic symptoms 
against a clinical interview with the Brief Psychiatric Rating Scale43 in a sample of psychotic 
patients, concluding that self-reported scores reflect clinical experience of psychosis.44 
Poulton et al14 presented strong evidence for predictive validity of CIDI self-reported 
psychotic symptoms. Similarly, Hanssen et al45 confirmed that the probability of having a 
psychotic disorder increased in a dose-response fashion with the level of self-reported 
psychotic experiences in the general population. In 2006, Konings et al46 confirmed the 
validity and reliability for the measurement of psychotic experiences with a selfreported 
instrument in the general population. A recent, 20-year longitudinal cohort study on psychotic 
symptoms using the SCL-90-R also showed high predictive validity of the SCL-90-R 
psychosis items used in the current sample in terms of deficiencies in social achievement and 
functioning.33  
 
Finally, the current studyhad a longitudinal, populationbased epidemiological perspective, 
contrasting with the shorter term, selective, sample-enriching approach focusing on help 
seekers in the ultrahigh-risk literature.36 The 2 perspectives and their respective populations, 
instruments, and outcomes are too different to make findings readily comparable.  
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